Ocugen
Latest round
- Series B
Last raised
- Jun 2017
Total raised
- $7.5M
Investors
- 2
About Ocugen
Ocugen, Inc.Founded in 2013 and headquartered in Malvern, US, Ocugen, Inc. specializes in gene therapies and vaccines. The firm has undergone strategic pivots, emphasizing innovative treatments for inherited retinal diseases and COVID-19. The company was founded by Shankar Musunuri, who has a history of entrepreneurial ventures.Ocugen, Inc. is a fully integrated, patient-centric biotechnology company that specializes in developing innovative healthcare solutions, primarily focusing on vaccines and gene and cell therapies. Their offerings include a mucosal vaccine for COVID-19 and a modifier gene therapy platform targeting inherited retinal diseases such as retinitis pigmentosa and Stargardt disease.In 2020, Ocugen, Inc. reported revenue of USD 42,620,000. However, the company's EBITDA for 2022 was negative at USD 84,487,000.Ocugen's growth strategy includes launching new products and expanding into new markets. Plans are in place to introduce additional gene therapies and vaccines by 2024. The firm is actively seeking to enhance its footprint in both North America and Asian markets.
Who invested in Ocugen
2 investors across 1 round
See all investors in Ocugen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jun 15, 2017
Amount
$7.5M
Investors
Questions about Ocugen
Who invested in Ocugen?
Ocugen has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ocugen raised?
Ocugen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ocugen last raise money?
Ocugen's most recent round on record is a Series B, in Jun 2017.
What does Ocugen do?
Ocugen is a biotechnology company.
Where is Ocugen headquartered?
Ocugen is headquartered in Malvern, US.
Which VCs invest in companies like Ocugen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ocugen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Ocugen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.